Price Chart

Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
URL https://www.auriniapharma.com
Investor Relations URL https://www.auriniapharma.com/investors-and-media
HQ State/Province Alberta
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
URL https://www.auriniapharma.com
Investor Relations URL https://www.auriniapharma.com/investors-and-media
HQ State/Province Alberta
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 15, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A